The decades-long battle over the 340B Drug Pricing Program has reached a boiling point. In a series of aggressive comment letters submitted this week, the pharmaceutical industry and hospital trade groups have once again “sharpened their spears.” At the heart of the dispute is a contentious federal pilot program—often dubbed the “mulligan” pilot—that aims to replace the traditional upfront discount model with a post-purchase rebate system.
While drugmakers like Johnson & Johnson (J&J) and industry advocates like PhRMA frame the move as a necessary step for “transparency,” hospital groups, led by the American Hospital Association (AHA), view it as a thinly veiled attempt to dismantle the safety-net program, projecting administrative costs that could exceed $1 billion.
1. The Core Conflict: Discount vs. Rebate
For over 30 years, the 340B program has allowed safety-net hospitals and clinics (covered entities) to purchase outpatient drugs at significant discounts—often 25% to 50% off the list price. These savings are intended to help providers stretch scarce federal resources to reach more eligible patients and provide more comprehensive services.
The Traditional Model (Upfront Discount)
Hospitals pay the discounted price at the “point of sale.” This preserves cash flow and minimizes administrative overhead for the healthcare providers who serve the most vulnerable populations.
The Proposed Model (Rebate Pilot)
Under the proposed pilot program, hospitals would pay the full wholesale acquisition cost (WAC) upfront. They would then submit data to drug manufacturers to prove the drug was dispensed to an eligible 340B patient, after which the manufacturer would issue a rebate.
2. PhRMA’s Stance: “Hospitals Adverse to Transparency”
Pharmaceutical Research and Manufacturers of America (PhRMA) has not minced words. In their latest filing, they accused hospitals of being “adverse to transparency,” claiming the current system is rife with duplicate discounts and drug diversion.
Key arguments from the Pharma side include:
Preventing Double-Dipping: Manufacturers argue that without a rebate system, they are often forced to pay both a 340B discount and a Medicaid rebate on the same unit of medicine—a practice prohibited by law but difficult to track under the current system.
Rampant Growth: The 340B program has exploded in size, reaching $147.8 billion in discounted purchases in 2024. PhRMA argues this growth has turned a safety-net program into a “corporate welfare” scheme for wealthy hospital systems.
Mandatory Participation: PhRMA is urging the Health Resources and Services Administration (HRSA) to skip the pilot phase and move directly to a mandatory rebate model for all 340B drugs by January 1, 2027.
3. The Hospital Counter-Attack: A $1 Billion Burden
The hospital industry’s response has been equally fierce. The AHA and groups like 340B Health argue that the rebate model is an “unlawful” and “unreasonable” attempt to add friction to the process, hoping hospitals will fail to navigate the red tape and thus forfeit their savings.
The Financial Math
The AHA recently updated its calculations regarding the administrative burden. While previous estimates suggested a $200 million labor cost, the latest analysis paints a much grimmer picture:
Administrative Costs: Hospitals estimate they will need to devote significantly more than the “two to five hours per week” projected by the government. The AHA now claims total administrative costs for 340B hospitals alone will exceed $1 billion.
Cash Flow Crisis: By forcing hospitals to “float” the full cost of expensive specialty drugs while waiting for rebates, the pilot could jeopardize the financial stability of rural and critical-access hospitals.
Complexity: A 340B Health survey of over 500 hospitals found that the rebate system would divert critical resources away from patient care to manage data reporting and rebate tracking.
4. The Legal and Regulatory “Mulligan”
The term “mulligan” (a do-over in golf) has been applied to this pilot because it follows a previous, failed attempt to implement similar changes. In early 2025, the Department of Health and Human Services (HHS) agreed to toss an earlier version of the rebate pilot following legal setbacks and fierce opposition from the hospital lobby.
However, the debate was reignited by a Senate HELP Committee report in April 2025, which called for increased transparency and data reporting. This emboldened the current administration to revisit the rebate mechanism as a compromise between the warring industries.
5. What’s at Stake for Patients?
While the industry giants spar over balance sheets, the ultimate impact will be felt by patients in underserved communities.
If Pharma wins: The program may become more “transparent,” but the increased costs and reduced cash flow could force safety-net hospitals to cut services, such as free clinics, oncology programs, or discounted pharmacy programs.
If Hospitals win: The upfront discount remains, but the pressure from Congress and manufacturers to address “program integrity” will not disappear.
Conclusion: A Deadlock with No End in Sight
The 340B rebate pilot is more than just a procedural change; it is a fundamental shift in the power dynamic between the pharmaceutical industry and the American healthcare system. With PhRMA pushing for a 2027 deadline and hospitals threatening further litigation, the “mulligan” pilot is likely headed for a long, drawn-out battle in the federal courts.
Frequently Asked Questions (FAQ)
1. What is the 340B Program? It is a federal program that requires drug manufacturers to provide outpatient drugs to eligible healthcare organizations (safety-net providers) at significantly reduced prices.
2. Why do drug companies want a rebate model? They claim it increases transparency and prevents “duplicate discounts” (where they pay both a 340B discount and a Medicaid rebate on the same drug).
3. Why do hospitals oppose the rebate model? Hospitals argue it creates a massive administrative burden (estimated at $1 billion), hurts their cash flow, and is a tactic used by drugmakers to limit the payouts they are legally required to provide.
4. What is a “covered entity” in 340B? These are the organizations eligible for the discounts, including HRSA-supported health centers, look-alikes, and certain types of hospitals like Disproportionate Share Hospitals (DSH) and Children’s Hospitals.
5. When will the 340B rebate pilot start? PhRMA is pushing for a start date no later than January 1, 2027, but ongoing litigation and hospital opposition mean the timeline remains uncertain.